FROM 01 December Australian
doctors and their patients will have
access to a new treatment for
bipolar 1 disorder on the PBS,
Saphris (asenapine).
Saphris is currently approved for
the treatment of: acute manic or
mixed episodes associated with
bipolar 1 disorder in adults;
prevention of relapse of manic or
mixed episodes in bipolar 1 disorder
and schizophrenia in adults.
Following the PBS December
listing the 5mg and 10mg drug will
be PBS reimbursed for: treatment
for up to six months, of an episode
of acute mania or mixed episodes
associated with bipolar 1 disorder;
maintenance treatment, as
monotherapy, of bipolar 1; and the
treatment of schizophrenia.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Nov 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Nov 11
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FROM 01 May, pharmacists will be able to dispense Verzenio (abemaciclib) through the PBS to treat Australian patients with an invasive form of early breast cancer that is at high risk of recurring after initial treatment.
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.